Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Author index

Page Path
HOME > Browse articles > Author index
Search
Na Diao 1 Article
IBD
Changes in the clinical course and prognosis of ulcerative colitis in Chinese populations: a retrospective cohort study
Xinyu Liu, Qingfan Yang, Na Diao, Jian Tang, Zicheng Huang, Xiang Gao, Kang Chao
Intest Res 2024;22(3):357-368.   Published online May 7, 2024
DOI: https://doi.org/10.5217/ir.2023.00106
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Data on the natural course of Chinese patients with ulcerative colitis (UC) was lacking. This study aimed to evaluate the natural history and prognosis of patients with UC in the past 15 years in China.
Methods
This cohort study included patients with UC in a tertiary hospital in southern China from 2007 to 2021 (cohort I: 2007–2011, cohort II: 2012–2016, cohort III: 2017–2021). Patients’ clinical characteristics and natural history were analyzed retrospectively.
Results
Of 1,139 included patients, 683 patients presented with proctitis or left-sided colitis at diagnosis and 38.5% of them (263/683) developed proximal disease extension. Fifty-eight percent of patients experienced relapse, chronic continuous and intermittent active course. Five patients (0.4%) developed colorectal tumors/dysplasia. The overall surgery rate was 8.6%, and the rates were 14.2%, 7.8%, and 8.0% in the 3 cohorts, respectively (P= 0.059). Average time from diagnosis to surgery decreased from cohorts I to III (144 months vs. 36 months, P< 0.001), so did the use of glucocorticoids (58.2% vs. 43.5%, P< 0.001) and immunosuppressants (14.1% vs. 13.4%, P= 0.016), and days of hospitalization (13 days vs. 9 days, P< 0.001). Biologics were used more frequently during the first year (0.8%, 2.1%, and 13.7% for cohorts I to III, respectively; P< 0.001). The rate of mucosal healing increased over time.
Conclusions
In Chinese UC patients, one-third of patients experienced proximal disease extension. The rates of malignancy and mortality were low. More biologics were used, while use of immunosuppressants and glucocorticoids were reduced over time. Early biologics use seemed to promote mucosal healing, but the rate of colectomy has not dramatically decreased.

Citations

Citations to this article as recorded by  
  • Manejo de la proctitis ulcerosa refractaria
    Manuel Barreiro-de Acosta, Francisco Mesonero, Rocío Ferreiro-Iglesias, Santiago García-López, Mariam Aguas Peris, Mónica Sierra Ausín, Noelia Cano Sanz, Antonio Valdivia Martínez, Ana Cábez, Susan Ramírez, Daniel Ginard
    Gastroenterología y Hepatología.2026; 49(5): 502646.     CrossRef
  • Leveraging patient-reported outcomes and serum markers to predict active ulcerative colitis: a multicenter cohort
    Wenqian Li, Xin Hao, Yunyun Sun, Caimin Li, Mei Wang, Sicong Hou
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • Management of refractory ulcerative proctitis
    Manuel Barreiro-de Acosta, Francisco Mesonero, Rocío Ferreiro-Iglesias, Santiago García-López, Mariam Aguas Peris, Mónica Sierra Ausín, Noelia Cano Sanz, Antonio Valdivia Martínez, Ana Cábez, Susan Ramírez, Daniel Ginard
    Gastroenterología y Hepatología (English Edition).2026; 49(5): 502646.     CrossRef
  • Distinct predictive factors for acute severe ulcerative colitis in East Asian and Western populations
    Eun Soo Kim, Dong Hyun Kim, Seong-Jung Kim, Sang Hyoung Park, Hyun Seok Lee, Sung Kook Kim, Hyun Soo Kim, Jun Lee, Kyeong Ok Kim, Byung Ik Jang, Yoo Jin Lee, Eun Mi Song, Dae Sung Kim, Chun-Chi Lin, Joyce Wing Yan Mak, Jing Liu, Qian Cao, Shu-Chen Wei, We
    Inflammatory Bowel Diseases.2026; 32(10): 1957.     CrossRef
  • Targeting mitochondrial dysfunction with traditional Chinese medicine for inflammatory bowel disease: a comprehensive review
    Linxi Zeng, Yao Huang, Jiayi Ke, Jiaqi Han, Wenda Xie, Zhishan Ding, Fangmei Zhou
    Frontiers in Pharmacology.2026;[Epub]     CrossRef
  • ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment
    Michel Adamina, Peter Kienle, María Chaparro, Bram Verstockt, Silvia Minozzi, Mariangela Allocca, Raja Atreya, Nicolas Avellaneda, Manuel Barreiro-De Acosta, Robert Battat, Dominik Bettenworth, Irina Blumenstein, Steven R Brown, John P Burke, Flavio Capri
    Journal of Crohn's and Colitis.2026;[Epub]     CrossRef
  • Five‐Year Outcomes and Disease Trajectories in Moderate‐to‐Severe Ulcerative Colitis: A Korean Multicenter Inception Cohort
    Byong Duk Ye, Hyo Jong Kim, Dong Il Park, Young Sook Park, Kang‐Moon Lee, Jong Pil Im, Sung‐Ae Jung, Yoon Tae Jeen, Jae Myung Cha, Jae Hee Cheon, Sung Noh Hong, Youngdoe Kim, Jong Min Choi, YoungJa Lee, Chang Kyun Lee
    Journal of Gastroenterology and Hepatology.2026; 41(8): 2338.     CrossRef
  • The effects of biologics on ulcerative colitis–related colectomy rate: results of a 22-year study
    Nur Beyza Tukek, Oguz Kagan Bakkaloglu, Gozde Sen, İbrahim Hatemi, Aykut Ferhat Celik, Yusuf Ziya Erzin
    Scandinavian Journal of Gastroenterology.2025; 60(6): 548.     CrossRef
  • Towards an Asian paradigm of inflammatory bowel disease management: A comparative review of China and Japan
    Qi Sun, Zhixian Jiang, Lichao Yang, Hao Liu, Peipei Song, Lianwen Yuan
    Intractable & Rare Diseases Research.2025; 14(3): 192.     CrossRef
  • Therapeutic management and risk of colectomy in patients with acute severe ulcerative colitis and previous exposure to anti-tumor necrosis factor drugs: a comparative study of GETECCU
    Francisco Mesonero, López-García Alicia, Miranda-Bautista José, Rubín de Célix Cristina, Marín-Jiménez Ignacio, Suárez Ferrer Cristina, Martin-Cardona Albert, Fuentes-Valenzuela Esteban, Mínguez Alejando, Castaño Andrés, Roig Cristina, Fernández-Clotet Ag
    Journal of Crohn’s and Colitis.2025;[Epub]     CrossRef
  • 11,770 View
  • 237 Download
  • 9 Web of Science
  • 10 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP